Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial.
Adults
Attention-deficit
Dialectical behavioral therapy (DBT)
Group therapy
Hyperactivity disorder (ADHD)
Non-pharmacological treatment
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
12
05
2022
accepted:
31
10
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
1
12
2022
Statut:
epublish
Résumé
Studies on structured skills training groups have indicated beneficial, although still inconclusive, effects on core symptoms of ADHD in adults. This trial examined effects of Dialectical Behavioral Therapy-based group treatment (DBT-bGT) on the broader and clinically relevant executive functioning and emotional regulation in adults with ADHD. In a multicenter randomized controlled trial, adult patients with ADHD were randomly assigned to receive either weekly DBT-bGT or treatment as usual (TAU) during 14 weeks. Subsequently, participants receiving TAU were offered DBT-bGT. All were reassessed six months after ended DBT-bGT. Primary outcomes were the Behavior Rating Inventory of Executive Function (BRIEF-A) and the Difficulties in Emotion Regulation Scale (DERS). Secondary outcomes included self-reported ADHD-symptoms, depressive and anxiety symptoms, and quality of life. We used independent samples t- tests to compare the mean difference of change from pre- to post-treatment between the two treatment groups, and univariate linear models adjusting for differences between sites. In total, 121 participants (68 females), mean age 37 years, from seven outpatient clinics were included, of whom 104 (86%) completed the 14-week trial. Entering the study, 63% used medication for ADHD. Compared to TAU (n = 54), patients initially completing DBT-bGT (n = 50) had a significantly larger mean reduction on the BRIEF-A (-12.8 versus -0.37, P = 0.005, effect size 0.64), and all secondary outcomes, except for symptoms of anxiety. All significant improvements persisted at 6 months follow-up. Change on DERS did not differ significantly between the groups after 14 weeks, but scores continued to decrease between end of group-treatment and follow-up. This DBT-bGT was superior to TAU in reducing executive dysfunction, core symptoms of ADHD and in improving quality of life in adults with ADHD. Improvements sustained six months after ended treatment. The feasibility and results of this study provide evidence for this group treatment as a suitable non-pharmacological treatment option for adults with ADHD in ordinary clinical settings. The study was pre-registered in the ISRCTN registry (identification number ISRCTN30469893, date February 19
Sections du résumé
BACKGROUND
Studies on structured skills training groups have indicated beneficial, although still inconclusive, effects on core symptoms of ADHD in adults. This trial examined effects of Dialectical Behavioral Therapy-based group treatment (DBT-bGT) on the broader and clinically relevant executive functioning and emotional regulation in adults with ADHD.
METHODS
In a multicenter randomized controlled trial, adult patients with ADHD were randomly assigned to receive either weekly DBT-bGT or treatment as usual (TAU) during 14 weeks. Subsequently, participants receiving TAU were offered DBT-bGT. All were reassessed six months after ended DBT-bGT. Primary outcomes were the Behavior Rating Inventory of Executive Function (BRIEF-A) and the Difficulties in Emotion Regulation Scale (DERS). Secondary outcomes included self-reported ADHD-symptoms, depressive and anxiety symptoms, and quality of life. We used independent samples t- tests to compare the mean difference of change from pre- to post-treatment between the two treatment groups, and univariate linear models adjusting for differences between sites.
RESULTS
In total, 121 participants (68 females), mean age 37 years, from seven outpatient clinics were included, of whom 104 (86%) completed the 14-week trial. Entering the study, 63% used medication for ADHD. Compared to TAU (n = 54), patients initially completing DBT-bGT (n = 50) had a significantly larger mean reduction on the BRIEF-A (-12.8 versus -0.37, P = 0.005, effect size 0.64), and all secondary outcomes, except for symptoms of anxiety. All significant improvements persisted at 6 months follow-up. Change on DERS did not differ significantly between the groups after 14 weeks, but scores continued to decrease between end of group-treatment and follow-up.
CONCLUSIONS
This DBT-bGT was superior to TAU in reducing executive dysfunction, core symptoms of ADHD and in improving quality of life in adults with ADHD. Improvements sustained six months after ended treatment. The feasibility and results of this study provide evidence for this group treatment as a suitable non-pharmacological treatment option for adults with ADHD in ordinary clinical settings.
TRIAL REGISTRATIONS
The study was pre-registered in the ISRCTN registry (identification number ISRCTN30469893, date February 19
Identifiants
pubmed: 36443712
doi: 10.1186/s12888-022-04356-6
pii: 10.1186/s12888-022-04356-6
pmc: PMC9706966
doi:
Banques de données
ClinicalTrials.gov
['NCT02685254']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
738Informations de copyright
© 2022. The Author(s).
Références
JAMA Psychiatry. 2015 Dec;72(12):1199-210
pubmed: 26536057
BMC Psychiatry. 2017 Aug 22;17(1):302
pubmed: 28830387
Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65
pubmed: 27866355
J Atten Disord. 2012 Oct;16(7):544-52
pubmed: 21725028
Eur Psychiatry. 2019 Feb;56:14-34
pubmed: 30453134
J Atten Disord. 2020 Mar;24(5):768-779
pubmed: 26838557
J Atten Disord. 2015 Mar;19(3):260-71
pubmed: 24874347
J Atten Disord. 2009 Sep;13(2):175-87
pubmed: 19372500
Behav Res Ther. 2011 Mar;49(3):175-85
pubmed: 21295767
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
J Affect Disord. 2018 May;232:41-47
pubmed: 29477097
Qual Life Res. 2006 Feb;15(1):117-29
pubmed: 16411036
J Atten Disord. 2020 Apr;24(6):875-888
pubmed: 27554190
J Atten Disord. 2019 Jan;23(1):76-86
pubmed: 25555629
Atten Defic Hyperact Disord. 2014 Mar;6(1):35-47
pubmed: 24132867
J Atten Disord. 2019 Feb;23(4):351-362
pubmed: 26588940
Neuropsychiatr Dis Treat. 2017 Jan 27;13:221-232
pubmed: 28184164
Lakartidningen. 2010 Mar 17-23;107(11):756-9
pubmed: 20402266
Ann Intern Med. 2017 Jul 4;167(1):40-47
pubmed: 28630973
Atten Defic Hyperact Disord. 2010 Jun;2(2):59-72
pubmed: 21432591
J Affect Disord. 2013 May;147(1-3):80-6
pubmed: 23218897
Psychol Med. 2005 Feb;35(2):245-56
pubmed: 15841682
Atten Defic Hyperact Disord. 2018 Sep;10(3):223-235
pubmed: 29492784
Perspect Clin Res. 2011 Oct;2(4):137-44
pubmed: 22145124
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
Psychol Med. 2019 Jan;49(1):55-65
pubmed: 29486807
J Atten Disord. 2017 Nov;21(13):1105-1120
pubmed: 24305060
J Pers Disord. 2004 Feb;18(1):73-89
pubmed: 15061345
Acta Psychiatr Scand. 2021 Jul;144(1):50-59
pubmed: 33749845
Eur Arch Psychiatry Clin Neurosci. 2002 Aug;252(4):177-84
pubmed: 12242579
J Consult Clin Psychol. 1988 Dec;56(6):893-7
pubmed: 3204199
Acta Psychiatr Scand. 2018 Feb;137(2):125-137
pubmed: 29282731
JAMA. 2010 Aug 25;304(8):875-80
pubmed: 20736471
J Nerv Ment Dis. 2013 Oct;201(10):894-900
pubmed: 24080677
Psychol Med. 2020 Mar;50(4):529-541
pubmed: 32036811
Atten Defic Hyperact Disord. 2016 Jun;8(2):101-11
pubmed: 26410823
JAMA Netw Open. 2019 May 3;2(5):e194980
pubmed: 31150084
J Atten Disord. 2009 Mar;12(5):434-41
pubmed: 18310557
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
J Subst Abuse Treat. 2015 Jun;53:52-9
pubmed: 25682718
J Nerv Ment Dis. 2018 Sep;206(9):739-743
pubmed: 30124570
Atten Defic Hyperact Disord. 2010 Dec;2(4):203-12
pubmed: 21432607
Eur Neuropsychopharmacol. 2018 Oct;28(10):1059-1088
pubmed: 30195575
J Clin Psychol. 2021 Mar;77(3):516-524
pubmed: 32880953
J Nerv Ment Dis. 2007 Dec;195(12):1013-9
pubmed: 18091195
Appl Neuropsychol Adult. 2021 Apr 27;:1-12
pubmed: 33905287
J Atten Disord. 2019 Jul;23(9):1047-1058
pubmed: 28745107
Eur Psychiatry. 2019 Sep;61:41-48
pubmed: 31288209
Eur Arch Psychiatry Clin Neurosci. 2017 Apr;267(3):267-276
pubmed: 27752827
J Atten Disord. 2020 Apr;24(6):904-917
pubmed: 28178870
J Affect Disord. 2012 Dec 15;142(1-3):241-7
pubmed: 22840630